$AVPT

Stephens raises Avepoint stock price target to $17 on AI tailwinds

Stephens raised its price target for Avepoint Inc. (NASDAQ: AVPT) to $17.00 from $16.00, citing AI-driven growth potential and strong financial performance. The company reported Q2 2026 earnings of $0.12 per share and revenue of $124.5 million, exceeding estimates. Avepoint's stock trades at $13.19, with a Fair Value of $15.15 according to InvestingPro.

Original reporting
Published Sep 21, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 12:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AVPT
Bullish
medium confidence
Mentioned
$AVPT
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AVPTBullishLow
01

Why it matters

The upgrade could attract new buying interest, but the underlying earnings were already disclosed weeks earlier.

02

Market read

Analyst target raise may provide a modest catalyst for AVPT, but overall market impact is limited.

03

What to watch

Potential FX pressure and higher spending could curb margins.

Relevance 4/10Novelty 2/10Timing: today

Background

Analyst from Stephens upgrades AvePoint, raising price target from $16 to $17 after Q2 beat.

Company-level read

Ticker impact

$AVPTBullishMedium confidence
Context

Stephens raised its price target on AvePoint to $17, citing AI-driven growth and strong Q2 results.

Expected impact

Potential modest price increase toward new target.

Evidence & confidence

Target raise reflects confidence in growth, but earnings were already public, limiting novelty.

Market effects

Highlights AI tailwinds for data‑protection software sector.

US mid‑cap software names may see modest interest.

Limited to investors tracking AI‑enabled enterprise software.

Counterpoint

Price target may be overly optimistic given macro‑headwinds.

Key entities

  • AvePoint Inc.

    Mid‑cap software provider focused on data protection and governance.

  • Stephens

    Equity research firm issuing the price‑target raise.

Related articles

$AVPTMedAI 9/10

AvePoint (AVPT) Q2 2026 Earnings Call Transcript

AvePoint (AVPT) reported Q2 2026 revenue of $124.5M, up 22% YoY, with SaaS revenue $98.5M (79% of total). Total ARR was $465.1M (+27%), net new ARR $29.9M, and GAAP operating margin 8.2%. Full-year guidance: ARR $522.1M-$528.1M and revenue $508.5M-$512.5M. The company also spent $50M on share repurchases in Q2.

$AVPTHighAI 9/10

AvePoint lifts annual recurring revenue guidance after Q2

AvePoint reported Q2 2026 revenue of $124.5M and raised full-year annual recurring revenue guidance. SaaS revenue was $98.5M, up 27% y/y, and ARR ended at $465.1M, up 27%. Q3 revenue is forecast at $128.2M to $130.2M, and full-year ARR at $522.1M to $528.1M. The company cited demand for AI governance.

$AVPTHigh

AvePoint Announces Second Quarter 2026 Financial Results

AvePoint, Inc. (AVPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 AvePoint Announces Second Quarter 2026 Financial Results Second quarter SaaS revenue of $98.5 million, representing 27% year-over-year growth, 26% on a constant currency basis Second quarter Total revenue of $124.5 million, representing 22% year-over-year growth, 21%

$BEAMMedAI 8/10

Beam Therapeutics reports early data on gene therapy for GSDIa

Beam Therapeutics (BEAM) reported early Phase 1/2 trial data for BEAM-301, a gene therapy for GSDIa, showing dose-dependent improvements in fasting hypoglycemia and reduced starch intake. The trial enrolled six patients, with median follow-up of 313 days for the 20 mg cohort and 53 days for the 40 mg cohort. All patients experienced adverse events, but no serious safety concerns were reported. The company will discuss the data at an investor event on October 27.

$MRKLow

Merck appoints Paul Diaz to board of directors

Merck & Co. (NYSE:MRK) announced Paul J. Diaz, managing partner at Cressey & Company, will join its board of directors effective November 1, 2026. Diaz will stand for election by shareholders in May 2027, expanding the board to 14 members. He brings healthcare industry leadership experience from roles at Myriad Genetics and Kindred Healthcare.